Early experience of atezolizumab plus bevacizumab therapy in Japanese patients with unresectable hepatocellular carcinoma in real-world practice
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Early experience of atezolizumab plus bevacizumab therapy in Japanese patients with unresectable hepatocellular carcinoma in real-world practice
Authors
Keywords
-
Journal
INVESTIGATIONAL NEW DRUGS
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2021-09-29
DOI
10.1007/s10637-021-01185-4
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Updated treatment recommendations for hepatocellular carcinoma (HCC) from the ESMO Clinical Practice Guidelines
- (2021) A. Vogel et al. ANNALS OF ONCOLOGY
- Initial Experience of Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma in Real-World Clinical Practice
- (2021) Hideki Iwamoto et al. Cancers
- Predictors of Response and Survival in Immune Checkpoint Inhibitor-Treated Unresectable Hepatocellular Carcinoma
- (2020) Pei-Chang Lee et al. Cancers
- Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
- (2020) Richard S. Finn et al. NEW ENGLAND JOURNAL OF MEDICINE
- LBA-3 CheckMate 459: Long-term (minimum follow-up 33.6 months) survival outcomes with nivolumab versus sorafenib as first-line treatment in patients with advanced hepatocellular carcinoma
- (2020) B. Sangro et al. ANNALS OF ONCOLOGY
- Exploratory Analysis of Lenvatinib Therapy in Patients with Unresectable Hepatocellular Carcinoma Who Have Failed Prior PD−1/PD-L1 Checkpoint Blockade
- (2020) Tomoko Aoki et al. Cancers
- Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline
- (2020) John D. Gordan et al. JOURNAL OF CLINICAL ONCOLOGY
- Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2019) Andrew X Zhu et al. LANCET ONCOLOGY
- Clinical Practice Guidelines for Hepatocellular Carcinoma: The Japan Society of Hepatology 2017 (4th JSH‐HCC Guidelines) a 2019 update
- (2019) Norihiro Kokudo et al. HEPATOLOGY RESEARCH
- Early Relative Change in Hepatic Function with Lenvatinib for Unresectable Hepatocellular Carcinoma
- (2019) Atsushi Hiraoka et al. ONCOLOGY
- Diagnosis, Staging and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases
- (2018) Jorge A. Marrero et al. HEPATOLOGY
- Analysis of the liver functional reserve of patients with advanced hepatocellular carcinoma undergoing sorafenib treatment: Prospects for regorafenib therapy
- (2018) Takeshi Terashima et al. HEPATOLOGY RESEARCH
- EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
- (2018) Peter R. Galle et al. JOURNAL OF HEPATOLOGY
- Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
- (2018) Masatoshi Kudo et al. LANCET
- Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma
- (2018) Ghassan K. Abou-Alfa et al. NEW ENGLAND JOURNAL OF MEDICINE
- Validation of Modified ALBI Grade for More Detailed Assessment of Hepatic Function in Hepatocellular Carcinoma Patients: A Multicenter Analysis
- (2018) Atsushi Hiraoka et al. Liver Cancer
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2018) Freddie Bray et al. CA-A CANCER JOURNAL FOR CLINICIANS
- IMbrave150: A randomized phase III study of 1L atezolizumab plus bevacizumab vs sorafenib in locally advanced or metastatic hepatocellular carcinoma.
- (2018) Richard S. Finn et al. JOURNAL OF CLINICAL ONCOLOGY
- Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2017) Jordi Bruix et al. LANCET
- Fever within 2 Weeks of Sorafenib Therapy Predicts Favorable Treatment Efficacy in Patients with Advanced Hepatocellular Carcinoma
- (2016) Teiji Kuzuya et al. ONCOLOGY
- Second-line ramucirumab therapy for advanced hepatocellular carcinoma (REACH): an East Asian and non-East Asian subgroup analysis
- (2016) Joon Oh Park et al. Oncotarget
- Assessment of Liver Function in Patients With Hepatocellular Carcinoma: A New Evidence-Based Approach—The ALBI Grade
- (2015) Philip J. Johnson et al. JOURNAL OF CLINICAL ONCOLOGY
- Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics
- (2012) Y Kanda BONE MARROW TRANSPLANTATION
- Early Decrease in α-Fetoprotein, but Not Des-γ-Carboxy Prothrombin, Predicts Sorafenib Efficacy in Patients with Advanced Hepatocellular Carcinoma
- (2011) Teiji Kuzuya et al. ONCOLOGY
- Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma
- (2010) Riccardo Lencioni et al. SEMINARS IN LIVER DISEASE
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
- Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
- (2008) Ann-Lii Cheng et al. LANCET ONCOLOGY
- Sorafenib in Advanced Hepatocellular Carcinoma
- (2008) Josep M. Llovet et al. NEW ENGLAND JOURNAL OF MEDICINE
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now